SPD 535
Alternative Names: SPD-535Latest Information Update: 15 Jan 2019
At a glance
- Originator Shire Pharmaceuticals Group
- Developer Shire
- Class Antiplatelets; Antithrombotics; Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 31 Dec 2012 Discontinued - Phase-II for Thrombosis in United Kingdom (unspecified route)
- 08 Dec 2011 Phase-II clinical trials in prevention of Thrombosis in United Kingdom in patients with arteriovenous grafts and undergoing haemodialysis (unspecified route)